The current investigation demonstrates the usefulness of the proposed protocol to measure FMRP levels and of mGluR5 expression in brain regions relevant for FXS to provide sound foundations for quantitation before, during, and after clinical trials of glutamatergic agents. Here, FMR1 is linked to fragile X syndrome.